Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.
Djuro Kosanovic, Andrey I Yaroshetskiy, Natalia A Tsareva, Zamira M Merzhoeva, Natalia V Trushenko, Galina V Nekludova, Ralph Theo Schermuly, Sergey N Avdeev
Author Information
Djuro Kosanovic: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Andrey I Yaroshetskiy: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Natalia A Tsareva: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Zamira M Merzhoeva: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Natalia V Trushenko: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Galina V Nekludova: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Ralph Theo Schermuly: Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.
Sergey N Avdeev: I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. Electronic address: serg_avdeev@list.ru.
Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.
